Profile data is unavailable for this security.
About the company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
- Revenue in USD (TTM)8.08m
- Net income in USD-58.29m
- Incorporated2017
- Employees64.00
- LocationJanux Therapeutics Inc10955 Vista Sorrento Parkway, Suite 200SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 751-4493
- Fax+1 (302) 655-5049
- Websitehttps://www.januxrx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics | 0.00 | -36.01m | 2.84bn | 50.00 | -- | 5.43 | -- | -- | -0.7623 | -0.7623 | 0.00 | 8.20 | 0.00 | -- | -- | 0.00 | -14.61 | -- | -16.09 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Amicus Therapeutics, Inc. | 399.36m | -151.58m | 3.06bn | 517.00 | -- | 18.95 | -- | 7.67 | -0.5148 | -0.5148 | 1.35 | 0.5456 | 0.5318 | 0.8939 | 5.19 | 772,448.80 | -20.18 | -30.65 | -25.36 | -36.55 | 90.65 | 88.94 | -37.96 | -86.10 | 2.52 | -1.76 | 0.7077 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Apogee Therapeutics Inc | 0.00 | -83.99m | 3.06bn | 91.00 | -- | 6.91 | -- | -- | -1.74 | -1.74 | 0.00 | 7.86 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| Azenta Inc | 641.02m | -17.37m | 3.09bn | 3.50k | -- | 1.26 | 44.16 | 4.82 | -0.2978 | -0.315 | 10.31 | 43.86 | 0.2096 | 2.86 | 3.40 | 183,149.40 | -0.568 | -0.5934 | -0.6169 | -0.6725 | 39.12 | 43.08 | -2.71 | -2.17 | 5.33 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Immunocore Holdings PLC - ADR | 249.43m | -55.29m | 3.09bn | 497.00 | -- | 8.35 | -- | 12.40 | -1.13 | -1.13 | 4.99 | 7.42 | 0.4439 | 0.3994 | 5.82 | 501,867.20 | -9.84 | -27.55 | -12.51 | -36.82 | 99.58 | -- | -22.17 | -97.12 | 3.77 | -173.40 | 0.1152 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Arrowhead Pharmaceuticals Inc | 181.74m | -296.81m | 3.12bn | 525.00 | -- | 16.86 | -- | 17.15 | -2.77 | -2.77 | 1.69 | 1.49 | 0.2395 | -- | -- | 346,171.40 | -39.91 | -20.02 | -46.61 | -24.65 | -- | -- | -166.63 | -61.79 | -- | -55.19 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Summit Therapeutics Inc | 0.00 | -614.93m | 3.14bn | 105.00 | -- | 40.37 | -- | -- | -1.54 | -1.54 | 0.00 | 0.1107 | 0.00 | -- | -- | 0.00 | -141.83 | -77.32 | -152.22 | -86.35 | -- | -- | -- | -20,989.46 | -- | -110.40 | 0.5628 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| Ideaya Biosciences Inc | 23.38m | -112.96m | 3.22bn | 124.00 | -- | 4.51 | -- | 137.77 | -1.96 | -1.96 | 0.4068 | 9.55 | 0.0451 | -- | 204.23 | 188,580.60 | -21.78 | -19.17 | -23.09 | -21.05 | -- | -- | -483.07 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Janux Therapeutics Inc | 8.08m | -58.29m | 3.22bn | 64.00 | -- | 8.35 | -- | 398.94 | -1.34 | -1.34 | 0.1837 | 7.44 | 0.0217 | -- | -- | 126,296.90 | -15.66 | -- | -16.31 | -- | -- | -- | -721.18 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Fortrea Holdings Inc | 3.11bn | -3.40m | 3.25bn | 18.00k | -- | 1.86 | 34.92 | 1.04 | -0.0379 | -0.0379 | 35.03 | 19.58 | -- | -- | -- | 172,722.20 | -- | -- | -- | -- | 16.74 | -- | -0.1094 | -- | -- | 1.27 | 0.478 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -182.39m | 3.26bn | 251.00 | -- | 3.51 | -- | -- | -2.73 | -2.73 | 0.00 | 12.31 | 0.00 | -- | -- | 0.00 | -21.22 | -20.71 | -21.86 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 3.26bn | 1.26k | -- | 4.54 | -- | 5.22 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.43bn | 305.00 | -- | 6.05 | -- | 129.73 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Ultragenyx Pharmaceutical Inc | 442.59m | -613.35m | 3.58bn | 1.28k | -- | 25.48 | -- | 8.08 | -8.02 | -8.02 | 5.75 | 1.69 | 0.329 | 1.61 | 6.18 | 346,854.20 | -45.59 | -33.35 | -55.09 | -38.30 | 88.59 | 93.13 | -138.58 | -154.71 | 2.28 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
Data as of May 07 2024. Currency figures normalised to Janux Therapeutics Inc's reporting currency: US Dollar USD
54.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 04 Mar 2024 | 9.17m | 17.74% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.67m | 9.04% |
| BVF Partners LPas of 31 Dec 2023 | 4.58m | 8.87% |
| Citadel Advisors LLCas of 31 Dec 2023 | 3.12m | 6.04% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.92m | 3.72% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 1.54m | 2.99% |
| Adage Capital Management LPas of 31 Dec 2023 | 1.36m | 2.62% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 953.60k | 1.85% |
| Geode Capital Management LLCas of 31 Dec 2023 | 408.19k | 0.79% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 347.59k | 0.67% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
